OC
SONM icon

Oppenheimer & Co’s DNA X Inc SONM Stock Holding History

Oppenheimer & Co’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24
Closed -$35K – 1340
2020
Q2 		$35K Hold
24
– – ﹤0.01% 1241
2020
Q1 		$30K Sell
24
-47
-66% -$225K ﹤0.01% 1170
2019
Q4 		$465K Buy
71
+37
+109% +$183K 0.01% 862
2019
Q3 		$181K Buy
+34
New +$522K ﹤0.01% 1161

Other funds holding SONM

BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Nokomis Capital Dallas, Texas $349M AUM 75.66% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
HIM
Herald Investment Management London, United Kingdom $737M AUM 158.15% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Oppenheimer & Co's SONM Position: Q3 2020 in Review

Oppenheimer & Co sold out of DNA X Inc (SONM) in Q3 2020, closing a stake of 24 shares — an estimated $35K sold.

Oppenheimer & Co first reported a position in SONM in Q3 2019 and held it in 4 quarters. The position peaked at $465K in Q4 2019. 34 funds tracked by Wall St. Rank hold SONM as of Q3 2020.

  • Oppenheimer & Co reported no remaining DNA X Inc position as of Q3 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 24 DNA X Inc shares in Q3 2020, an estimated $35K.
  • Oppenheimer & Co first reported a position in DNA X Inc in Q3 2019 and held it in 4 quarters.
  • Oppenheimer & Co's DNA X Inc position peaked at $465K in Q4 2019.
  • 34 funds tracked by Wall St. Rank held DNA X Inc as of Q3 2020.

Based on Oppenheimer & Co's 13F filing for Q3 2020, filed 13 Nov 2020.